

**IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF ILLINOIS**

-----X

FALCONER PHARMACY, INC., on behalf of itself and  
all other similarly situation,

Civil Action No.

Plaintiff,

**JURY TRIAL DEMANDED**

v.

SURESCRIPTS, LLC; RELAYHEALTH; and  
ALLSCRIPTS HEALTHCARE SOLUTIONS INC.,

Defendants.

-----X

**PLAINTIFF'S CLASS ACTION COMPLAINT**

Plaintiff Falconer Pharmacy, Inc. (“Plaintiff”) brings this action individually, and on behalf of a class of all persons and entities similarly situated (the “Class”), for damages and injunctive relief under the antitrust laws of the United States against defendants Surescripts, LLC (“Surescripts”), RelayHealth, and Allscripts Healthcare Solutions, Inc. (“Allscripts”) (together, the “Defendants”). Plaintiff alleges facts regarding itself based on personal knowledge, and all other facts below on information and belief after an investigation by counsel. Plaintiff believes that discovery of the Defendants, and third parties, will uncover evidence supporting the allegations made on information and belief.

### **I. NATURE OF THE CASE**

1. This is an action under Sections 1 and 2 of the Sherman Act to restrain anticompetitive conduct by Surescripts, the nation’s largest provider of “e-prescribing” services, and to remedy the harms of its decade-long anticompetitive scheme.

2. The details of this scheme first became public on May 3, 2019 when the Federal Trade Commission (“FTC”) filed a lawsuit against Surescripts in the United States District Court for the District of Columbia.

3. Surescripts has engaged in a long- running anticompetitive scheme to maintain its monopolies over two separate, complementary markets: (1) electronic prescription routing (“routing”) and (2) eligibility, which are often collectively referred to as “e-prescribing.” Routing is the transmission of prescription and prescription-related information from a prescriber (via the prescriber’s electronic health record (“EHR”) system) to a pharmacy. Eligibility is the transmission of a patient’s formulary and benefit information from a payer (usually the patient’s pharmacy benefit manager (“PBM”)) to a prescriber’s EHR.

4. In 2009, Surescripts had monopolies over routing and eligibility. With both of these markets poised to experience explosive growth due to federal incentives for e-prescribing, Surescripts feared that other health information technology companies could threaten its dominant positions. To neutralize these competitive threats, Surescripts took a series of anticompetitive actions to protect and maintain its monopolies. This multifaceted anticompetitive scheme has been remarkably successful: Despite a massive increase in e-prescribing over the past decade, Surescripts has prevented any meaningful competition, maintaining at least a 95% share (by transaction volume) in each market.

5. First, Surescripts changed its pricing policies to require long-term exclusivity from nearly all of its routing and eligibility customers. Surescripts designed its new pricing to ensure that its customers would pay a higher price on all of Surescripts's transactions unless they were "loyal" to Surescripts, i.e., used Surescripts exclusively. With its 95%-plus share in both markets, Surescripts knew that no competitor could ever offer customers enough savings to compensate customers for the skyrocketing costs the customers would face by paying Surescripts's higher "non-loyal" price on their remaining Surescripts transactions. Surescripts's web of loyalty contracts prevented competitors from attaining the critical mass necessary to be a viable competitor in either routing or eligibility. Those effectively exclusive contracts foreclosed at least 70% of each market, eliminating multiple competitive attempts from other companies, such as Emdeon, that offered lower prices and greater innovation. All of this was done intentionally, as one Surescripts vice president gloated about how Surescripts's loyalty contracts scheme excluded a competitor, Emdeon: "It[']s nice when a plan comes together." Another executive testified under oath, "pricing isn't dictated by competition at Surescripts."

6. Second, Surescripts has engaged in a long-running campaign of threats and other non-merits-based competition to ensure that no other competitor could get a toehold in either market. For example, when Allscripts, a large EHR customer of Surescripts, attempted to enter into a non-exclusive agreement with Surescripts in 2014 so Allscripts could use Emdeon, Surescripts launched a series of threats-what senior Surescripts executives called their “nuclear missiles.” These threats were intended to secure Allscripts’s continued exclusive use of Surescripts and quash the threat from Emdeon. Allscripts ultimately chose to join the anticompetitive scheme instead of fighting Surescripts. Thus, the competitive threat from Emdeon as a routing provider was eliminated.

7. Third, Surescripts eliminated the competitive risk posed by RelayHealth, a subsidiary of McKesson Corporation, in routing. Surescripts feared that RelayHealth-with its extensive connections to many of the same customers Surescripts wanted to lock up via its loyalty scheme-had a “natural ability to capture 15-20% of transaction volume.” Surescripts understood that competition from RelayHealth would have “dropped the price [for routing] down to 2 to 3 cents at any time.” To eliminate this competitive risk, in 2010, Surescripts and RelayHealth entered into an agreement that prohibited RelayHealth from competing in the routing market for six years. Although this agreement facially preserved the existing “value-added reseller” relationship between the two companies, Surescripts executives have repeatedly stated that, from Surescripts’s perspective, the sole benefit of that ongoing relationship is that it sidelines RelayHealth as a competitor. In return for its acquiescence in the anticompetitive scheme, RelayHealth received a portion of the supracompetitive routing profits as a “reseller.” Although the formal non-compete is no longer in the agreement, strict contract provisions continue to prevent RelayHealth from competing against

Surescripts in routing, ensuring that the routing market suffers from the effects of that non-compete today.

8. Due to Defendants' ongoing conduct, there is no meaningful competition in the markets for routing or eligibility. The decade-long monopolies in these markets have produced predictable effects: higher prices, reduced quality, stifled innovation, suppressed output, and stymied alternative business models. Pharmacies, like Plaintiff here, typically pay at least *17 cents* per routing transaction under Surescripts' monopolistic regime. Surescripts has admitted that competitive prices in the routing market would be between *1 and 3 cents* a transaction. Using Surescripts' own numbers, revealed by the Federal Trade Commission investigation, Plaintiffs have paid, and continue to pay, routing prices that are inflated by *at least 566-1700%* due to Defendants' anticompetitive conduct.

9. These pennies add up for independent pharmacies, Plaintiff and members of the Class. In 2013, 1 billion new and refill prescriptions were routed to pharmacies electronically. In 2018, Surescripts claims it processed 1.9 billion e-prescriptions alone.<sup>1</sup> That adds up to *billions* of overcharge transactions and supracompetitive prices during the class period.

10. Had Surescripts' 1.9 billion e-prescriptions in 2018 been routed at competitive prices instead of monopoly prices, Plaintiff and the Class would have saved millions of dollars in that year alone. And this scheme has been underway for almost a decade.

## II. JURISDICTION AND VENUE

11. This action arises under sections 1 and 2 of the Sherman Act, 15 U.S.C. §§ 1-2, section 4 of the Clayton Act, 15 U.S.C. § 15(a). Plaintiff seeks damages for its injuries, and those suffered by members of the Class, resulting from Defendants' anticompetitive conduct that

---

<sup>1</sup> <https://surescripts.com/news-center/national-progress-report-2018/>

inflated the price of e-prescription routing services to pharmacies. This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331(federal question), 1337(a) (antitrust), and 15 U.S.C. § 15 (antitrust).

12. The Court also has jurisdiction over this action pursuant to 28 U.S.C. § 1332(d) because this is a class action in which the aggregate amount in controversy exceeds \$5,000,000 and at least one member of the putative class is a citizen of a state different from that of Surescripts.

13. Defendants transact business within this district, and they transact their affairs and carry out interstate trade and commerce, in substantial part, in this district and/or have an agent and/or can be found in this district. Venue is appropriate within this district under section 12 of the Clayton Act, 15 U.S.C. § 22 (nationwide venue for antitrust matters), and 28 U.S.C. §1391(b) and (c) (general venue provisions).

### **III. PARTIES**

14. Plaintiff Falconer Pharmacy, Inc. is a pharmacy located in Falconer, New York. Plaintiff has paid Surescripts e-prescription routing charges.

15. Defendant Surescripts is a for-profit Delaware limited liability company, with its principal place of business at 2800 Crystal Drive, Arlington, VA 22202. Except where otherwise specified, “Surescripts” refers to Surescripts, LLC and all corporate predecessors, subsidiaries, successors, and affiliates.

16. Defendant RelayHealth is a corporation organized under the laws of the State of Delaware, with its principal place of business at 561145 Sanctuary Parkway, Alpharetta, GA 30009. RelayHealth, a division of McKesson Technologies Inc., is a wholly-owned subsidiary of McKesson Corporation.

17. Defendant Allscripts Healthcare Solutions, Inc. is a corporation organized under the laws of the State of Delaware, with its principal place of business at 222 Merchandise Mart Plaza, Suite 2024, Chicago, IL 60654. Except where otherwise specified, “ Allscripts” refers to Allscripts Healthcare Solutions, Inc. and all corporate predecessors, subsidiaries, successors, and affiliates.

18. Defendants’ Co-conspirators: Generally, a pharmacy technology vendor (“PTV”) only provides a pharmacy with pharmacy software and computer technology that facilitates a pharmacy’s connection to the Surescripts routing service, other claims adjudication services, eligibility and benefit network messaging, and clinical messaging systems (among other things). PTVs design the software conduits that allow pharmacies to access and use Surescripts routing. Pharmacies pay Surescripts for routing e-prescriptions and are itemized per routing transaction.

19. However, upon information and belief, some PTV entities joined Defendants’ scheme as co-conspirators, aiders and abettors, and otherwise acted in concert with Defendants in connection with Surescripts’ monopolization of the e-prescription routing market (“PTV Co-Conspirators”). Some PTV and health information technology company co-conspirators contract with Surescripts or RelayHealth to “resell” Surescripts’ e-prescription routing transactions in return for a cut of the supracompetitive profits. These pharmacy technology vendors and health information technology companies agreed to de facto or de jure exclusive dealing contracts with Surescripts and/or RelayHealth and thus expressly entered into anticompetitive agreements restraining trade and maintaining Surescripts’ monopoly control of the routing market. Routing prices charged to pharmacies by PTV Co-Conspirators move in lock-step with Surescripts’ prices. Though not all are currently known or named as defendants in this complaint, the PTV Co-Conspirators are nonetheless complete, voluntary, and substantially equal co-conspirators in

the furtherance of Surescripts' anticompetitive scheme. Surescripts requires that all PTVs be "certified" with Surescripts in order to provide pharmacies with access to the Surescripts routing network. The PTVs "certified" by Surescripts include, but are not limited to: Abacus, AdvanceNet Health Solutions, AMS Visions, AdvancedRx by HealthLink Solutions, Automated Healthcare Solutions, A-S Medication Solutions, Amis Pharmacy, AmberRx, AIS/Lynx, BDM Pharmacy, BestRx Pharmacy Software, BioMed Intelligence (BMI) – RxVector, Benecard Services, Carepoint – GuardianRx, Cerner Etreby, Compusolve, Computer-Rx, Cost Effective – QuickSCRIP, CPR+, Creehan Company – ScriptMed, Cypress Rx, CpERx, DAA Enterprises, Data Doc, Inc., Datascan, Digital Business Solutions – Digital Rx, Doctor Dispense, Epic, EnterpriseRx, Enclara Pharmacia, eRx Network, Foundation Systems Inc. (FSI), HBS Rx, HCC, InstyMeds, Integra, JASCORP, KeyCentrix, Koogly, Kalos, Lagniappe Pharmacy Services, LexiCom, Liberty Software, McKesson Pharmacy Systems, MDScripts, Mediware, Micro Merchant Systems – PrimeRx, 5mRx LLC, NowRx – QuickFill, Omnicare, OPUS-ISM, Pacific Pharmacy Computers (PPC), Pharmascan, Pharmacy Computer Services (Rx3000), Pharmacy Systems, Inc., PioneerRx, PK Software, Prodigy Data Systems Inc. – PROscript 2000, PamLab, PD-Rx Pharmaceuticals, Pharmacy Data Management, Prime Therapeutics, LLC – RxExpress, QuiqMeds, QS/1, Retail Data Systems – Easy Rx, RNA – Helix, RS Software, Rx Outreach, RNA Holdings – Triad Retail Pharmacy System, RxLinc, ScriptPro, Software Strategics, Inc., SoftWriters – FrameWorkLTC, Speed Script, SRS, SuiteRx, Supervalu – Arx, ScriptDash – Wunderbar, StreamCare, THOT, Transaction Data Systems – Rx30, VIP Computer systems, VendRx, WesCom, and Zadall Pharmacy System. Over 79% of the routing market is controlled by anticompetitive exclusive dealing Surescripts contracts.

#### IV. BACKGROUND

##### A. Electronic prescribing consists of two transactions.

20. E-prescribing is the electronic transmission of prescription or prescription-related information between a prescriber (through the prescriber's EHR), a pharmacy, and a payer (usually a PBM), either directly or through an intermediary.

21. E-prescribing developed as a safer, more accurate, efficient, and lower-cost means for prescribers (via their EHRs), pharmacies, and PBMs to communicate and process patient prescriptions. The benefits of e-prescribing include fewer medical errors due to poor handwriting, greater awareness of potential adverse drug interactions, more effective communication of a patient's insurance coverage and generic alternatives, and increased adherence (the likelihood that a patient will pick up a prescription at a pharmacy after leaving the prescriber's office).

22. The core e-prescribing services are routing and eligibility. Although these two services are usually provided to prescribers together in the same prescribing workflow, each transaction serves a different purpose, delivers different information, and occurs between different customers.

23. Routing is the transmission of prescription and prescription-related information between the prescriber's EHR and a pharmacy. Routing transactions also include the transmission of a pharmacy's request to a prescriber's EHR for a refill of a prescription.

24. Eligibility is the transmission of a patient's formulary and benefit information from a PBM to a prescriber's EHR prior to the patient's appointment. This information allows a prescriber to know, for example, which drugs are covered by the patient's drug benefit plan, the location of covered drugs on a patient's health insurance company's formulary, and what

copay (if any) a patient will have to pay to obtain a prescribed drug. Eligibility also informs the prescriber of lower-cost alternatives, such as generic drugs.

25. Each of the routing and eligibility transactions is governed by its own industry-wide standard created by the National Council for Prescription Drug Programs (“NCPDP”). There is no patent or other intellectual property protection for either the routing or the eligibility transactions.

**B. Routing and eligibility are two-sided networks with a “chicken-and-egg problem.”**

26. Providing routing requires building a two-sided network (or platform) linking EHRs to pharmacies. Providing eligibility requires building a two-sided network (or platform) linking EHRs to PBMs.

27. Two-sided platforms experience what economists refer to as “indirect network effects.” That means that the value to participants on one side increases when there are more participants on the other side.

28. Both routing and eligibility have significant indirect network effects. For routing, pharmacies get more value from a network that connects to more EHRs because there is a greater supply of prescribers that can send patients to those pharmacies to purchase the patients’ prescribed drugs. And EHRs get more value from a network that connects to more pharmacies because prescribers can send prescriptions to more pharmacies, which increases the likelihood that patients will be able to use their preferred pharmacy.

29. Similarly, for eligibility, PBMs get more value from a network that connects more EHRs, as the increased distribution of a PBM’s formulary and benefit information helps more prescribers prescribe on-formulary drugs and thereby saves PBMs more money. And the EHRs get more value from a network that connects to more PBMs because EHRs are able to obtain

more complete insurance benefit information, such as for those patients who have multiple insurers.

30. Another feature of many two-sided networks is that customers on one side of the network will not join the network unless they are confident that they will be able to access enough customers on the other side and thereby derive enough value from using the network. Neither side will join unless they believe the other side will. This gives rise to what economists refer to as the “chicken-and-egg problem.” Solving this coordination problem is key to developing a viable platform.

31. Routing and eligibility both face the chicken-and-egg problem, as the industry itself has observed. For routing, a network is unlikely to persuade EHRs to join the network, and incur the costs associated with connecting, unless those EHRs believe they will be able to access a substantial number of pharmacies on that network. And a routing network is unlikely to convince pharmacies to join the network, and incur the costs associated with connecting, unless those pharmacies believe they will be able to access a substantial number of EHRs participating in that network.

32. For eligibility, a network is unlikely to persuade EHRs to join the network, and incur the costs associated with connecting, unless those EHRs believe they will be able to access a substantial number of PBMs on that network. And an eligibility network is unlikely to convince PBMs to join the network, and incur the costs associated with connecting, unless those PBMs believe they will be able to access a substantial number of EHRs participating in that network.

33. Creating viable routing and eligibility networks requires solving the chicken-and-egg problem and providing sufficient value to both sides of these platforms.

Economists recognize that to solve the chicken-and-egg problem networks must get a “critical mass” of customers on both sides to sign up. If a network cannot get a critical mass on both sides, then it is unlikely to be able to operate a viable platform.

34. In its submissions to the FTC, Surescripts has acknowledged that the chicken-and-egg problem exists as a barrier to entry in each of the markets for routing and eligibility.

35. When a new platform starts, it can achieve critical mass either by getting customers who have not signed on to any platform or by getting customers from an existing platform. Customers of an existing platform face less cost and risk when they can use both their current platform and the new platform. Economists refer to the use of more than one platform simultaneously as “multihoming.” Multihoming is common and new platforms routinely rely on multihoming to enter and compete with existing platforms.

36. Nearly all routing and eligibility customers use Surescripts’s platform, so competitors in general must compete for customers already using Surescripts’s routing and eligibility platforms. Because customers often prefer to avoid the cost and risk of a complete switch to an entrant, the entrant is most likely to win business through multihoming, i.e. utilize companies or platforms other than Surescripts. Customers want to multihome because it encourages price competition and innovation in e-prescribing, and a small handful do multihome. As alleged below, Surescripts intentionally set out to substantially increase all routing and eligibility customers’ costs to multihome, significantly elevating the critical mass a Surescripts competitor would need to become a viable network in either routing or eligibility.

Absent Surescripts's conduct, entrants in routing and/or eligibility would have used multihoming to overcome the chicken-and-egg entry barrier through normal, market-based competition.

**C. Due to federal policies and incentives, the e-prescribing industry has experienced extraordinary growth.**

37. In 2008, there had been limited adoption of e-prescribing by prescribers. Congress thus acted twice to encourage expansion of e-prescribing and its many benefits.

38. First, on July 15, 2008, Congress passed the Medicare Improvements for Patients and Providers Act ("MIPPA"). MIPPA, through regulations implemented by the Centers for Medicare and Medicaid Services ("CMS"), adopted a carrot-and-stick approach to encourage prescribers to e-prescribe. As the carrot, MIPPA provided financial incentives to prescribers equivalent to a reimbursement bonus based on the prescriber's total charges for professional services to Medicare and Medicaid. As the stick, MIPPA established penalties in the form of reduced Medicare and Medicaid reimbursements to prescribers if a prescriber was not a "successful electronic prescriber." To be considered a successful electronic prescriber under MIPPA, a prescriber must use an EHR that, among other things, allows the prescriber to obtain eligibility information and "electronically transmit prescriptions" for a specified fraction of total prescriptions.

39. Second, on February 17, 2009, Congress passed the Health Information Technology for Economic and Clinical Health Act ("HITECH Act"), which further expanded the regulatory regime CMS implemented to grow e-prescribing. The HITECH Act encourages the "meaningful use" of EHRs throughout the United States. It does so by authorizing carrot-and-stick financial incentives and payment reductions to prescribers depending on whether they "meaningfully used" EHR technology. Through today, CMS has paid out over \$38 billion in

meaningful use financial incentives, which does not account for the effect of the potential penalties.

40. One meaningful use objective is the ability to “[g]enerate and transmit prescriptions electronically.”

41. To prescribe electronically-and thus obtain the financial incentives and later avoid penalties described above-prescribers (via their EHRs) need to connect to pharmacies and PBMs.

42. From 2008 to 2016, the number of routing and eligibility transactions grew over 23-fold, from 147 million to 3.5 billion, and the percentage of U.S. physicians e-prescribing grew to nearly 70%. In 2017, 77% of all prescriptions were delivered electronically.

43. This growth was primarily driven by MIPPA and the HITECH Act. Surescripts agrees, writing in 2014, “[w]e believe the dramatic growth in adoption and use [of e-prescribing] is a function of the combined forces of federal financial incentives and an aggressive response by the technology sector.” As Surescripts’s former CEO Harry Totonis testified, “meaningful use totally helped e-prescribing happen.”

**D. Surescripts was well positioned to capitalize on e-prescribing’s explosive growth.**

44. Surescripts, LLC was formed on May 9, 2008, through a cashless merger of two companies: Rx.Hub LLC (“Rx.Hub”) and SureScripts Systems, Inc. (“SureScripts Systems”). The merger was not reportable under the Hart-Scott-Rodino Act and neither the U.S. Department of Justice nor the FTC reviewed the merger.

45. Rx.Hub was the first major eligibility network. It was formed by three PBMs in February 2001.

46. Six months later, in response to RxHub's formation, two pharmacy trade groups formed SureScripts Systems. SureScripts Systems primarily focused on routing.

47. As a result of the merger, Surescripts possessed at least 95% of the routing market (by transaction volume) and at least 95% of the eligibility market (by transaction volume).

48. Surescripts is currently owned by CVS Health ("CVS") (17%) (a pharmacy and PBM), Express Scripts (33%) (a PBM), the National Association of Chain Drug Stores (25%) (a trade association), and the National Community Pharmacists Association (25%) (a trade association).

49. No EHR or prescriber has an ownership interest in Surescripts.

50. No pharmacy or PBM, other than CVS and Express Scripts, has a direct ownership interest in Surescripts.

51. No pharmacy, PBM, or EHR has a controlling interest in Surescripts.

52. Surescripts provides connections between EHRs, pharmacies, and PBMs for routing and eligibility.

53. Surescripts charges pharmacies (either directly or indirectly via a reseller or other third-party intermediary, such as a pharmacy technology vendor ("PTV")) a fee for each routing transaction and charges PBMs a fee for each eligibility transaction.

54. In 2016, Surescripts received routing and eligibility fees from pharmacies, PBMs, and intermediaries, which accounted for a substantial part of its revenue.

55. Surescripts pays EHRs a fee for each routing and eligibility transaction, but only if the EHR uses Surescripts exclusively. The industry commonly refers to these disbursements as "incentive payments."

56. In 2016, Surescripts made incentive payments to EHRs.

57. Surescripts follows the NCPDP standards for routing and eligibility transactions.

58. Surescripts creates and manages its own certification processes for its network, which means that customers (i.e., EHRs, pharmacies, PBMs, and intermediaries) must obtain certification from Surescripts and sign a contract before they can use Surescripts's network.

## V. ANTICOMPETITIVE CONDUCT

59. In 2009, Surescripts, with its extensive connectivity to prescribing stakeholders was well positioned to benefit from enormous growth in routing and eligibility, which was catalyzed by MIPPA, the HITECH Act, CMS regulations, and a broader movement towards computerizing health records. Surescripts foresaw a vast, open, and untapped market. However, other companies saw the same potential.

60. Surescripts faced substantial competitive threats to its routing and eligibility monopolies and was concerned that competition would drive the "commoditization" of routing and eligibility, reduce prices for each, and "devastate" Surescripts's cash flow.

61. In late September 2009, Surescripts's management explained to its board of directors that these "competitive pressures require precipitous price drops, down near or below our average unit costs (-5c)" and that, should Surescripts "lose 2-3 midsize pharmacy customers or a large PBM" to a competitor, "Surescripts would not be financially viable."

62. To prevent lower prices from competition, Surescripts substantially raised nearly all its customers' costs to multihome, rendering the chicken-and-egg problem insoluble for a competitor. The result has been the total exclusion of all meaningful competition in routing and eligibility, higher prices, reduced innovation, lower output, and no customer choice.

**A. Surescripts learns of an emerging threat to its monopolies.**

63. On July 1, 2009, a health information technology company called Emdeon (n/k/a eRx Network) acquired eRx Network, a competing routing network. Although eRx Network only transmitted approximately 5% of routing market transactions at that time, it was well positioned for significant growth as eRx Network maintained connectivity with Allscripts, a large EHR, and PDX, a PTV providing routing connectivity that marketed primarily to medium-to-large sized retail pharmacy chains.

64. Surescripts recognized that competition from Emdeon would “drive lower prices.”

65. On July 22, 2009, Surescripts’s Chief Strategy Officer, Scott Barclay, explained that with “lower prices and further capabilities, the new Emdeon could significantly compete” with Surescripts.

66. If Emdeon could provide lower prices to pharmacies, higher incentives to EHRs, or both, Emdeon could attract enough customers to its routing network and solve the chicken- and-egg problem. Surescripts understood that if additional customers were to multihome with Emdeon, “[t]hen it becomes a price game at pharmacy and an incentive game at the POC [point of care, i.e., prescribers/EHRs]....[E]ach network fights for itself and the market share game becomes paramount quickly.”

67. Surescripts thus acted to eliminate the outbreak of competition—an outcome where one set of customers (pharmacies and PBMs) would pay lower prices, another set of customers (EHR.s) would receive higher incentive payments, but Surescripts would lose its supracompetitive profits.

**B. Surescripts responds to competition by devising and implementing an anticompetitive web of exclusive contracts.**

68. In response to the threat from Emdeon and other competitors, Surescripts, with its 95%-plus established share in both markets, sought to eliminate all competition by significantly raising its customers' costs to multihome, thereby dramatically increasing the critical mass necessary for a Surescripts competitor to become viable. Surescripts did so by blanketing the markets for routing and eligibility with loyalty pricing and exclusivity contracts.

69. Beginning in mid-2009, Surescripts devised a scheme to include "loyalty" provisions in contracts with customers on both sides of the routing and eligibility markets, which conditioned discounts or payments on actual or de facto exclusivity. Loyalty discounts apply to Surescripts's pharmacy, PTV, and PBM customers. Loyalty payments apply to Surescripts's EHR customers.

**1. The structure of Surescripts's pharmacy, PTV, and PBM contracts.**

70. For pharmacies and PTVs to receive a loyalty discount, a customer must deal exclusively with Surescripts. To be considered exclusive, Surescripts requires that a pharmacy and PTV customer route 100% of its transactions "through and only through the Surescripts network." This requirement only applies to Surescripts-connected entities. Because Surescripts maintains connectivity to nearly all EHRs, this provision effectively requires 100% exclusivity from pharmacies and PTVs. Surescripts generally refers to these exclusive customers as "loyal" customers and those that are not exclusive as "non-loyal."

71. The same eligibility structure exists for PBMs.

72. Under these loyalty provisions, because pharmacies, PTVs, and PBMs must use Surescripts for all or nearly all of their transactions, becoming non-exclusive and losing the loyalty discounts results in a significant cost increase. Surescripts's loyalty pricing scheme

therefore substantially increases the cost of multihoming through a second network for nearly all pharmacies, PTVs, and PBMs. Though the difference in the per-transaction price between a loyal and non-loyal transaction is often a few pennies, many pharmacy chains and PBMs send millions of transactions across the Surescripts network and a difference of a few pennies results in hundreds of thousands or even millions of dollars in cost increases.

73. These non-loyal per-transaction prices (which are additional costs to customers) are not justified by any increased costs faced by Surescripts in transmitting routing or eligibility information. Rather they exist only to act both as penalties to those customers that may consider being non-loyal to Surescripts and as an exclusionary tactic against any competitor in routing or eligibility, thus reinforcing and maintaining Surescripts's monopolies in routing and eligibility.

74. In many contracts, Surescripts also requires customers to pay the price differential between the loyal and non-loyal price for historical transaction volume retroactive over the term of the contract. For many customers, these additional clawback obligations total millions of dollars and substantially strengthen the lock-up effect of the contracts.

75. Surescripts refers to these clawback provisions as the "teeth" of its loyalty contracts.

76. For example, as the FTC has uncovered, Exhibit Two (A) of Surescripts's September 28, 2010 contract with a PTV provides an illustrative example of the "teeth" of Surescripts's contracts:

If, during the Loyalty Term, Aggregator [i.e., PTV] ceases to route all of its electronic Prescription Routing messages to Prescribing Participants through, and only through, the Surescripts network and fails to cure within the applicable cure period, then Surescripts shall immediately cease calculating the Loyalty

Discount and Aggregator agrees to pay Surescripts the amount of the Loyalty Discount received by Aggregator during the Loyalty Term.

77. Similarly, Surescripts's June 2, 2010 contract with PBM customer provides:

If, during the Loyalty Term, PBM ceases to route all of its electronic Prescription History and Benefit (Ambulatory) messages to Participants through, and only through, the Surescripts network, then Surescripts shall immediately cease applying the Loyalty Eligibility Transaction Fee price and PBM agrees to pay Surescripts the difference in the amount of Transaction Fees PBM would incur had PBM paid the [non-loyal price] versus the [loyal price] as of the Amendment Effective Date.

## **2. The structure of Surescripts's EHR contracts.**

78. Surescripts imposes the same loyalty scheme on EHRs, except in reverse by conditioning any incentive payments on an EHR's exclusivity to Surescripts for routing, eligibility, or both.

79. Under the EHR loyalty program as implemented for most EHRs, if an EHR agrees to be exclusive only in routing, Surescripts pays the EHR an incentive fee tied to the routing fee paid by pharmacy customers to Surescripts for each routing transaction. If an EHR agrees to be exclusive only in eligibility, Surescripts pays the EHR an incentive fee tied to the eligibility fee paid by PBM customers to Surescripts. If the EHR agrees to be exclusive in both routing and eligibility, Surescripts pays the EHR a higher incentive fee on both transactions. Nearly all EHRs participating in the loyalty program agree to exclusivity on both transactions.

80. If an EHR decides to multihome and use Surescripts for less than 100% of its transactions, Surescripts terminates incentive fees to that EHR. In other words, Surescripts raises the EHR's price by reducing the EHR's incentive fees to zero. As with the penalty price Surescripts charges non-loyal pharmacies, PTVs, and PBMs, there are no legitimate competitive reasons (e.g., increased costs) for Surescripts to raise its EHR price to zero for non-loyal EHRs.

81. As with its clawback provisions to pharmacies, PTVs, and PBMs, Surescripts also requires the EHR to pay back the incentive fees for historical transaction volume if the EHR violates the exclusivity commitment. Some contracts require repayment on transactions over the full term of the contract. For example, Surescripts's April 14, 2010 contract with EHR provides:

If, during the Loyalty Term, Surescripts determines that Aggregator [i.e., the EHR] has failed to comply with the loyalty requirements . . . Aggregator shall promptly pay back to Surescripts the amount of Incentive Fees paid by Surescripts to Aggregator during the Loyalty Term, and Aggregator shall no longer receive the Incentive Fees.

**3. Surescripts structured the contracts to lock up the routing and eligibility markets.**

82. Surescripts implemented loyalty pricing and exclusivity requirements to make the chicken-and-egg problem insurmountable for any competitor in either routing or eligibility (or both). Specifically, Surescripts's loyalty program substantially raises its customers' costs to multihome, significantly elevating the critical mass a competing platform would need to become viable, rendering the chicken-and-egg problem insoluble. As Surescripts explained in a presentation to its board, the new loyalty strategy would "[p]rotect [Surescripts's] most critical asset-[its] network-by addressing competitive market pressures and locking-in key customers."

83. Nearly all of Surescripts's loyalty pricing and exclusive contracts in both routing and eligibility have an initial term of three years or more. With some larger customers, the terms are as long as five years.

84. Surescripts prefers to employ long-term contracts because they enable Surescripts to lock up its customers, preventing them from using a competitor's network. As Surescripts's then-Vice President of Account Management explained in a February 2010

email to the company's then-CEO, "[o]ur 3 year commitments keep[] our competition out of those customers."

85. Nearly all of Surescripts's loyalty pricing and exclusive contracts in both routing and eligibility automatically renew for one year unless either party gives notice.

86. In early 2010, as demand for routing and eligibility was growing and inviting entry, Surescripts began executing loyalty pricing with nearly all of its e-prescribing customers. Most of these contracts had an effective date retroactive back to January 1, 2010.

**C. Surescripts and RelayHealth reject competition and entered into agreements to join forces and share Surescripts' monopoly profits to extend the reach of its exclusive contracts and solidify its monopolies.**

87. While Surescripts was able to push its loyalty pricing and exclusive contracts onto its direct customers, Surescripts was only able to lock up customers with whom Surescripts had a direct contract. But Surescripts was also concerned about a large subset of customers that it did not have direct contracts with (and thus did not have exclusivity commitments from)-namely those customers that connected to Surescripts through RelayHealth.

88. RelayHealth is a health information technology company that is a subsidiary of McKesson. Since 2003, RelayHealth has contracted with Surescripts to resell the routing transaction to a subset of pharmacy and PTV end-customers. RelayHealth contracts with these pharmacies and PTVs, but Surescripts does not. RelayHealth also provided Surescripts's routing connectivity to some EHRs until 2015, but it no longer does so except for EHRs associated with McKesson.

89. Surescripts sells the routing transaction to RelayHealth at a "wholesale" rate. RelayHealth then resells the transaction to a subset of pharmacies and PTVs at a higher "retail" rate. RelayHealth profits from the margin between the retail rate pharmacies and

PTVs pay RelayHealth and the lower wholesale rate RelayHealth pays to Surescripts. All else equal, the lower Surescripts's wholesale rate to RelayHealth, the higher RelayHealth's margin.

90. Through two contracts, one executed in 2010 and a second executed in 2015, Surescripts provided RelayHealth with contractual and monetary incentives to convince RelayHealth's routing customers to be loyal to the Surescripts routing network.

91. In the February 25, 2010 contract ("the 2010 contract") between Surescripts and RelayHealth, RelayHealth was required to use "commercially reasonable efforts to offer terms to incentivize exclusive use of the Surescripts network" by pharmacies, PTVs, and EHR.s and to assist Surescripts in clawing back any incentive fees from EHRs.

92. Under the 2010 contract, if a RelayHealth customer maintained exclusivity to Surescripts, Surescripts discounted its wholesale price to RelayHealth for that customer. Pursuant to the 2010 contract, RelayHealth entered into contracts with its pharmacies and PTVs for routing through the Surescripts network. Nearly all of these contracts went beyond the Surescripts requirement and mandated that these customers use RelayHealth exclusively (i.e., for 100% of their required transactions). Because RelayHealth was exclusive to Surescripts, this provision resulted in nearly all of RelayHealth's pharmacy and PTV customers routing all of their transactions through Surescripts. As an October 2012 RelayHealth presentation put it, RelayHealth's strategy was to "[m]ove non-exclusive customers to exclusive wherever possible."

93. RelayHealth also provided Surescripts with feedback as to RelayHealth's customers' exclusivity status. For example, in 2012, Surescripts instructed RelayHealth to

inquire into the loyalty status of a routing customer called Transaction Data Systems d/b/a Rx30 (“Rx30”). RelayHealth did so and informed Surescripts that Rx30 was not loyal.

94. Under the 2010 contract, RelayHealth also entered into contracts with EHRs for routing through the Surescripts network. These contracts were typically for a length of two years or more, contained express exclusivity requirements to RelayHealth, and provided incentive payments to EHRs only if an EHR was 90-100% exclusive to the Surescripts network. Again, because Surescripts was the only routing network to which RelayHealth provided access, this provision resulted in nearly all of RelayHealth’s EHR customers routing all of their transactions through Surescripts. For each exclusive routing transaction, Surescripts paid RelayHealth an incentive payment. RelayHealth then passed a portion of those incentives on to its EHRs, but only if they met RelayHealth’s exclusivity requirements.

95. RelayHealth’s contracts with EHRs also required repayment of all incentive fees paid to the EHR if the EHR failed to comply with RelayHealth’s exclusivity requirement.

96. In the next contract, signed on January 16, 2015 (“the 2015 contract”), Surescripts renewed its 2010 contract with RelayHealth with modifications. The contract provided RelayHealth with a higher wholesale discount for exclusive transactions; increased the loyalty threshold, instead of determining loyalty on a customer-by- customer basis, determined loyalty on a platform-wide basis.

97. As explained in more detail below, the 2015 contract also required RelayHealth to transfer its EHR connections to Surescripts. RelayHealth therefore no longer provides routing connectivity to EHRs, except for EHRs associated with McKesson.

98. Under the 2015 contract, RelayHealth has not changed its contracts with its end-user pharmacy and PTV customers to resell Surescripts’s routing connectivity. Thus,

RelayHealth's contracts for Surescripts's routing network continue to require 100% exclusivity through today.

**D. Surescripts Colludes with Allscripts to Exclude Routing Competitor Emdeon.**

99. While implementing this web of loyalty and exclusive contracts, Surescripts devoted special attention and resources to locking up a critical EHR: Allscripts. In 2009, Allscripts represented approximately 25% of Surescripts's routing and eligibility transactions, making it a significant customer for any e-prescribing network. Allscripts's EHR technology relied on a centralized "hub" infrastructure for all of its customers, meaning that if Allscripts multihomed with an additional e-prescribing network, the added e-prescribing network could quickly route e-prescriptions to and from Allscripts's entire e-prescribing customer base. Allscripts's exclusivity was critical to Surescripts two reasons: (1) Allscripts was one of the few EHRs that was multihoming, using Emdeon as an alternative routing network to Surescripts, which made Emdeon a more viable threat to Surescripts; and (2) Allscripts had implemented a new business model in eligibility that cut out Surescripts as the middleman.

100. First, Allscripts had contracted with Emdeon for routing since 2007. This connection allowed Allscripts to route prescriptions to Emdeon's pharmacy customers without utilizing the Surescripts network. Emdeon paid Allscripts a routing transaction incentive fee that was higher than what Surescripts paid Allscripts.

101. Surescripts recognized that Allscripts was crucial to Emdeon gaining scale in routing, overcoming the chicken-and-egg problem, and offering increased competition and lower prices. Access to Allscripts's routing transaction volume (through its prescribers) made Emdeon more attractive to potential pharmacy customers. In a November 17, 2009

email, a senior Surescripts executive wrote that in order to prevent Emdeon from solving the chicken-and-egg problem, “[t]he key to Emdeon is Allscripts[] (i.e., the key to fighting eRx networks [Emdeon] is containing their access to POC [point of care, i.e., prescribers]).”

102. Second, in September 2009, before Surescripts implemented its loyalty and exclusive contracts, Surescripts learned that Allscripts was transmitting eligibility requests around Surescripts’s network directly to a PBM called SXC Health Solutions. This practice of developing “direct connections” for eligibility with PBMs represented a different means for Allscripts to receive eligibility information from PBMs and, more broadly, a different model for e.-prescribing, one that cut out Surescripts as a middleman. From Surescripts’s perspective, Allscripts’s development of direct connections to PBMs made Allscripts “a major competitor and our largest current risk” in eligibility.

103. By May 2010, Allscripts sold or was attempting to sell direct connections to its prescriber network to at least six PBMs, often at prices below Surescripts’ s.

104. For example, Allscripts charged at least one PBM a per-transaction price that is lower than what that same PBM was paying to Surescripts for the same eligibility transaction.

105. PBMs hoped their relationships with EHRs would create a more competitive, innovative market that would exert pressure on Surescripts to innovate. Many customers have complained that Surescripts’s eligibility transaction is “not a reliable process” because it provides only static, non-patient specific formulary information.

106. Surescripts realized that Allscripts’s direct eligibility connections were “a long-term potential threat[] coming true.”

107. Facing these threats, Surescripts implemented a “full combat strategy” to “lock up . . . Allscripts” through an exclusive contract with Allscripts, which Allscripts and Surescripts signed on May 31, 2010.

108. As the preamble to that contract states, “the purpose of this [agreement] is to enter into a long term arrangement for [Allscripts] to utilize Surescripts exclusively” for both routing and eligibility.

109. The 2010 contract had a term of four years and included several provisions tailored specifically to Allscripts to ensure exclusivity from Allscripts for both routing and eligibility.

110. First, Surescripts required Allscripts to terminate its routing connection to the Emdeon network at the expiration of Allscripts’s contract with Emdeon in June 2013. Allscripts, despite its objections, agreed to this requirement to avoid losing access to Surescripts’s network. Surescripts’s network is a “must-have” for nearly all EHRs because EHRs must connect to pharmacies and PBMs to e-prescribe. Allscripts terminated its relationship with Emdeon on June 20, 2013.

111. Second, Surescripts grandfathered in Allscripts’s current direct connections with PBMs but prohibited Allscripts from renewing its eligibility contracts with those PBMs and from proactively marketing or entering into new eligibility agreements with PBMs.

112. Third, Surescripts imposed a “right of first refusal” procedure on Allscripts’s e-prescribing business: If any third party sought to do business with Allscripts in either routing or eligibility, Allscripts was required to set up a meeting with Surescripts and that third party “to facilitate a connection between such [third party] and Surescripts.” Only if the third party did not want to do business with Surescripts after this

meeting could Allscripts engage in business discussions with the third party for routing or eligibility.

113. Fourth, Surescripts required Allscripts to remind its sales and business development personnel annually of the above terms, and Surescripts maintained the right to “review and comment” on such annual reminders.

114. Surescripts realized that Allscripts was key to crushing Emdeon’s ability to expand and quashing any alternative e-prescribing business model via Allscripts’s direct connections to PBMs. Surescripts thus provided Allscripts with “enhanced” or “relatively more attractive revenue sharing.” Specifically, Surescripts paid Allscripts an incentive tied to the routing and eligibility fees paid by pharmacy and PBM customers for each transaction, substantially more than similarly situated EHRs. One slide from an internal Surescripts presentation, reproduced below, described an early version of its 2010 deal with Allscripts by including a picture of the movie poster from the 2009 film “The Proposal,” which included the slogan “HERE COMES THE BRIBE.”

115. In the five years following the execution of the contract, Surescripts paid Allscripts substantial amounts in incentives for routing and eligibility.

116. In 2014, though Surescripts had successfully pressured Allscripts into severing its routing connection with Emdeon, Surescripts still worried that Allscripts would restart multihoming, using Emdeon as an alternative, which would, in the words of Greg Hansen, Surescripts’ s then- Executive Vice President and Chief Customer Officer, “create what is essentially a bidding war for [Allscripts’s prescribers’] transactions or access to their physician community.”

117. To stifle this “bidding war” Surescripts engaged in a renewed campaign to force Allscripts into exclusivity.

118. In the second half of 2014, Surescripts threatened to withhold Allscripts’s access to Surescripts’s “must-have” e-prescribing network for routing and eligibility. Allscripts in turn feared that “Surescripts would have cut us off” if Allscripts did not sign a new exclusive agreement with Surescripts.

119. During the same time period, to secure Allscripts’s exclusivity, Surescripts also threatened (1) to bar Allscripts from using eligibility information obtained from Surescripts’s network for Allscripts’s electronic prior authorization transactions, which increases efficiency between prescribers and pharmacies by reducing the time it takes to receive pre-approval for certain prescription drugs from a patient’s insurer; (2) to cut Allscripts off from Surescripts’s pharmacy directory, which is necessary to allow a prescriber to locate a patient’s preferred pharmacy; and (3) to sever Allscripts’s access to a separate service called medication history, which Allscripts’s prescribers used in both acute and ambulatory settings.

120. Surescripts also sought to impose a penalty on Allscripts by making Allscripts pay millions of dollars if Allscripts did not enter into an exclusive agreement. For example, Surescripts sent Allscripts retroactive invoice for Allscripts’s use of what was supposed to be a separate free service offered by Surescripts if Allscripts did not agree to the exclusivity terms Surescripts had proposed. Surescripts also withheld loyalty incentive payments to Allscripts until Allscripts signed the contract.

121. Surescripts referred to these tactics as “nuclear missile[s]” and admitted they were designed to ensure that Allscripts would continue to use Surescripts

exclusively. Both Surescripts and Allscripts understood that these tactics were meant to “exert leverage” over Allscripts to force it to sign an exclusive agreement for routing and eligibility.

122. During this same period, Emdeon again attempted to sign Allscripts up as a customer by, for example, offering Allscripts increasingly large up-front payments and profit-sharing arrangements to compensate Allscripts for losing Surescripts’ s incentive fees.

123. Despite Emdeon’s efforts, Surescripts’s tactics with Allscripts were successful. On January 31, 2015, Allscripts signed a new amendment with Surescripts, extending the term of the underlying exclusive contract for five years.

124. On June 29, 2018, after Surescripts became aware that the FTC was investigating its conduct, Allscripts and Surescripts entered into a new amendment that deleted some of the more restrictive provisions contained in the 2010 Allscripts-Surescripts agreement and the 2015 amendment. That 2018 amendment, however, did not alter the fact that Allscripts was still required to use Surescripts exclusively for routing and eligibility or face financial penalties.

**E. Defendants’ scheme has succeeded in excluding all meaningful competition from both routing and eligibility.**

125. Over the last 10 years, Emdeon attempted unsuccessfully to expand its presence in the routing market and, later, in the eligibility market. Beginning in 2009, Emdeon attempted to convince pharmacies and EHRs to use its network to route transactions, circumventing the Surescripts network. Doing so would require these pharmacies and EHRs to become non-loyal to Surescripts or RelayHealth and pay back the discounts or incentive payments pharmacies and EHRs already received. In many cases,

Emdeon approached these potential customers with lower 28 per-transaction pricing than Surescripts charged, higher per-transaction incentive payments than Surescripts paid, and no loyalty requirements.

126. However, Emdeon was not successful. Many pharmacies and EHRs refused to connect to Emdeon, since doing so would trigger the massive penalty provisions in their contracts with Surescripts or RelayHealth and cost routing customers millions of dollars through increased prices or, for EHRs, decreased incentive payments. Because Emdeon could not expand its connectivity, it could not deliver low enough pricing on a high enough volume of transactions to make up for the huge penalties inflicted on any pharmacy or EHR that chose to become non-loyal to Surescripts. There was no price (or incentive payment) that Emdeon could offer that would offset the penalty customers would receive by becoming non-loyal to Surescripts.

127. Surescripts executives knew that its loyalty scheme was working as intended. They repeatedly admitted that Surescripts's web of exclusive contracts quashed any competitive threat. As Surescripts explained to a RelayHealth pharmacy end customer, Rite Aid, in early 2010, because of the loyalty scheme there was no price Emdeon could offer that would reduce Rite Aid's total routing costs:

## Clarifying the Issues



### **eRx/Emdeon cannot save Rite Aid money in e-prescription routing by splitting traffic:**

- While eRx/Emdeon may offer a low introductory price, they can only do so for a subset of your transactions
- Rite Aid would still need to route the great majority of transactions through Surescripts and RelayHealth
- The lowest transaction pricing from RelayHealth for Surescripts connectivity is only available when routing 100% of your transactions through us
- The total cost to Rite Aid to split traffic would therefore be higher than if you continue to route 100% through RelayHealth and Surescripts

---

Surescripts®

Confidential and Proprietary

128. In the above slide, Surescripts explained to Rite Aid how its loyalty scheme disrupted the price-setting mechanism of the routing market.

129. In September 2010, Surescripts articulated how its exclusive contracts restricted Emdeon's expansion and reduced its potential to reach critical mass:

Surescripts's efforts to lock in our customers through Loyalty programs have likely had a strong impact to Emdeon's initial strategy. With most top Prescriber Vendors signed to Loyalty Incentive plans, and, a significant portion of the Pharmacy industry signed to Loyalty pricing plans (direct and via [RelayHealth]), Emdeon's ability to expand their direct connection to prescribers and pharmacies has been greatly reduced. Emdeon's ability to rapidly become a full national alternative to Surescripts is diminished.

130. In October 2010, a Surescripts vice president wrote “the loyalty/incentive strategy and execution made a very effective counter to the Emdeon/eRX acquisition. It[']s nice when a plan comes together.”

131. In that same month, Surescripts described how its loyalty program foreclosed Emdeon from the market by disabling Emdeon’s ability to compete on price: “eRx/Emdeon can undercut Surescripts on price, but only on a margin of volume ... and Surescripts pricing differential on pharmacy side and loyalty incentive program on POC side are worth more than eRx / Emdeon’s proposition on <10% of scripts.”

132. When Emdeon’s initial efforts to expand failed, Emdeon attempted a new strategy designed to work around Surescripts’s massive financial penalty provisions. Emdeon resells the Surescripts routing transaction to a group of pharmacies that use a PTV called PDX. Emdeon sought to gain critical mass on the EHR side. With the PDX pharmacies disconnected from the Surescripts network, EHR.s would be free to route directly to Emdeon without incurring Surescripts’s penalties for being non-loyal. This is because under Surescripts’s contracts with EHRs, EHRs would not be penalized for routing to a pharmacy that could not be reached using the Surescripts network. Despite an organized campaign to attempt to sign up EHRs to contingent contracts (where the EHR would agree to route through Emdeon only if Emdeon disconnected its pharmacies from the Surescripts network), Emdeon was unable to execute enough contracts to obtain enough scale to become viable in e-prescribing and solve the chicken-and-egg problem. In the midst of this campaign, Allscripts severed its connection with Emdeon, as required by Allscripts’s 2010 agreement with Surescripts, a move Emdeon described as a “devastating” blow, and one that pushed Emdeon almost completely out of the market.

133. In late 2013, Emdeon again attempted to compete with Surescripts, this time in eligibility. Emdeon approached potential PBM customers with lower pricing than Surescripts as well as offers to innovate in ways that would respond to PBM complaints regarding the quality of Surescripts's eligibility service. Although Emdeon gained some traction, it ultimately could not acquire the critical mass of PBMs and EHR.s needed to overcome Surescripts's loyalty provisions.

## **VI. SURESCRIPTS POSSESSES MONOPOLY POWER IN EACH RELEVANT MARKET**

### **A. The relevant markets.**

134. There are two relevant product markets: (1) routing transactions; and (2) eligibility transactions.

135. Other means of transmitting routing and eligibility information (e.g., paper, phone, fax) are not reasonably interchangeable with electronic prescribing because of safety concerns and greater efficiencies associated with electronic prescriptions, as well as the requirements of MIPPA, the HITECH Act, and HHS regulations.

136. The relevant geographic market is the United States. Large pharmacy chains, EHRs, and PBMs that make up nearly all of routing and eligibility transactions have nationwide reach. Surescripts's customers enter into contracts with nationwide reach, and prices and contract terms are set at a national level. Federal laws and regulations that govern e-prescribing i.e., MIPPA, HITECH, and associated CMS regulations, operate on a national level, further supporting a national geographic market.

137. Thus, the relevant markets in which to evaluate Surescripts's conduct are (1) routing transactions in the United States; and (2) eligibility transactions in the United States.

**B. Surescripts possesses monopoly power in the relevant markets.**

138. Surescripts possesses durable monopoly power in each relevant market.

139. Surescripts has possessed monopoly power in each relevant market from 2009 to present.

140. There is substantial direct evidence that Surescripts possesses monopoly power.

141. Direct evidence of Surescripts's monopoly power includes its demonstrated ability to control price in each relevant market.

142. Surescripts has the ability to price substantially higher than its competitors in the routing market without losing customers. This includes both prices to pharmacies and incentives to EHRs.

143. Surescripts has the ability to price substantially higher than its competitors in the eligibility market without losing customers. This includes pricing to PBMs and incentives to EHRs.

144. Other direct evidence of Surescripts's market power includes the lack of any meaningful competition in either routing or eligibility from 2009 to the present. For example, when Surescripts refused to do business with a customer called PrescribersConnection in 2015, that customer was left with nowhere else to turn and as a result has had its e-prescribing functionality permanently disabled-a situation that persists today. Surescripts's customers agree that there are "no 1-1 alternatives to Surescripts," that Surescripts is a "must-have" network and a "monopolist for a key service."

145. There is substantial indirect evidence that Surescripts possesses monopoly power.

146. Surescripts possesses extremely high market shares in both relevant markets. Surescripts possesses at least 95% market share in the market for routing (by transaction volume). Surescripts possesses at least 95% market share in the market for eligibility (by transaction volume). As one Surescripts vice president put it in 2015: “We are a Monopoly when it comes [to] Prescription Routing.” Even if routing and eligibility were to be considered part of the same market, Surescripts’s own then-Executive Vice President and Chief Customer Officer testified that Surescripts’s market share in both products is “[l]ikely north of 90 percent.”

147. The markets for routing and eligibility are characterized by barriers to entry in the form of the chicken-and-egg problem, which Surescripts’s conduct has rendered unsolvable.

## **VII. SURESCRIPTS’S ANTICOMPETITIVE COURSE OF CONDUCT HARMED COMPETITION AND CONSUMERS**

148. Surescripts’s anticompetitive course of conduct has resulted in the total exclusion of any meaningful competition in e-prescribing, repeated threats to customers to force exclusivity, higher prices, reduced innovation, and lower output.

### **A. Surescripts’s conduct forecloses each market from all meaningful competition, eliminating consumer choice.**

149. Surescripts, whether directly or indirectly via RelayHealth, successfully imposed loyalty requirements on nearly all of its pharmacy and PTV customers. By January 2011, Surescripts had loyalty contracts with at least 78% of the pharmacy side of the routing market (by transaction volume), including contracts with major pharmacies such as CVS, Walgreens, Walmart, and Rite Aid. Nearly all of the loyalty contracts with these pharmacies have been renewed or amended with similar loyalty provisions, and they remain in place today. Currently,

Surescripts, whether directly or indirectly via RelayHealth, has loyalty contracts with at least 79% of pharmacy routing transaction volume. These contracts therefore foreclose nearly 80% of the pharmacy side of the routing network from potential competition. The result is to make multihoming substantially more expensive for customers, rendering the chicken-and-egg problem insoluble for Surescripts's competitors.

150. Surescripts also imposed loyalty requirements on nearly all of its PBM customers. By October 2011, Surescripts had exclusivity contracts with at least 74% of the PBM side of the eligibility market (by transaction volume), including contracts with major PBMs such as Express Scripts, CVS, and Medco. Nearly all of the loyalty contracts with these PBMs have been renewed or amended with similar loyalty provisions, and they remain in place today. Currently, Surescripts has exclusivity contracts with at least 78% of PBM eligibility transaction volume. These contracts therefore foreclose nearly 80% of the PBM side of the eligibility network from potential competition. The result is to make multihoming substantially more expensive for customers, rendering the chicken-and-egg problem insoluble for competitors.

151. Surescripts, whether directly or indirectly via RelayHealth, also imposed loyalty requirements on nearly all of its EHR customers. By November 2010, Surescripts had exclusivity contracts with at least 81% of the EHR routing market and at least 78% of the EHR eligibility market (both measured by transaction volume), including contracts with major EHRs such as Allscripts, Epic, and eClinicalWorks. Nearly all of the loyalty contracts with these entities have been renewed or amended with similar loyalty provisions, and they remain in place today. Currently, Surescripts-which in 2015 took direct control over nearly all of RelayHealth's routing contracts with EHRs-has loyalty contracts with at least 87% of EHR routing and eligibility transaction volume. These contracts therefore foreclose well

over 80% of the EHR sides of the routing and eligibility networks from potential competition. The result is to make multihoming substantially more expensive for customers, rendering the chicken-and-egg problem insoluble for competitors.

152. The foreclosure percentages in paragraphs 172-174 likely understate the foreclosure effects of Surescripts's conduct, which is based on contracts for Surescripts's largest routing and eligibility customers. There is a "long tail" of smaller Surescripts customers that are also foreclosed by the same loyalty contracts described above, which only further increases the percentage of each side of each market that Surescripts has been able to foreclose.

153. Surescripts's loyalty contracts disrupt competition in routing and eligibility. Because Surescripts has foreclosed at least 70-80% of each of the routing and eligibility markets, even when a competitor offers lower per-transaction prices, no customer will do business with that competitor because that competitor cannot lower the customer's total e-prescribing cost. Because of Surescripts's conduct, no competitor can gain enough scale to solve the chicken-and-egg problem and compete with Surescripts. Customers, including PBMs, EHRs, and pharmacies, are all harmed by not having any choice of routing or eligibility provider.

154. A pharmacy would sign up with a Surescripts competitor-and thus incur non-loyalty penalties via higher prices or clawbacks-only if the competitor can route enough prescriptions from EHRs that are priced low enough to create sufficient savings to offset the pharmacy's losses from the foregone Surescripts discounts. Likewise, an EHR will sign up with a Surescripts competitor-and thus incur non-loyalty penalties via eliminated incentive payments or clawbacks-only if the competitor can pay the EHR high enough incentives on a

sufficient number of transactions to offset the EHR's losses from the foregone Surescripts payments. This same logic applies to PBMs and EHRs for eligibility.

155. Surescripts's loyalty regime ensures that no customer could ever attain a lower *total* cost by multihoming, even if Emdeon or some other competitor offered that customer, in the words of one of Surescripts's former vice presidents, "some phenomenally low amount" on the transactions sent through Emdeon's network.

156. Pharmacies and PBMs receive discounts from Surescripts in exchange for agreeing to exclusivity. A competing platform that sought to convince a pharmacy or PBM to multihome would need to offer a lower price to compensate that customer for losing its loyalty discount with Surescripts. Due to the limited connections to EHRs that a competing platform could offer, the compensating price would have to be *negative*, meaning the competing platform would have to *pay* pharmacies and PBMs for each routing and eligibility transaction.

157. Similarly, EHRs receive incentive fees from Surescripts in exchange for agreeing to exclusivity. A competing platform that sought to convince an EHR to multihome would need to offer higher incentive fees to compensate that customer for losing its incentive fees from Surescripts. Due to the limited connections to pharmacies and PBMs that a competing platform could offer, the compensating incentive fees would be unprofitable for an equally efficient competitor.

158. By foreclosing approximately 80% of both markets and making the chicken-and-egg problem insoluble, Surescripts has ensured that no other competitor can be or remain viable in either routing or eligibility, or both.

**B. Surescripts forces its routing and eligibility customers into exclusivity.**

159. Many pharmacy, PBM, and EHR customers that have entered into loyalty contracts with Surescripts would prefer the option of having a competing network for routing and eligibility. However, because these pharmacies, PBMs, and EHRs compete with other pharmacies, PBMs, and EHRs, they cannot absorb higher e-prescribing costs and remain competitive. Thus, Surescripts's customers lack the realistic ability to refuse Surescripts's loyalty requirements or pricing.

160. As one Surescripts EHR customer explained, despite "strongly object[ing] to the ... exclusivity provisions" in Surescripts's contract, it had no choice but to agree to Surescripts's exclusivity provision "[b]ecause there were no alternative providers that could meet all of its needs." Though the customer recognized "that the inclusion of the exclusivity provisions provided Surescripts with the ability to protect its dominance in the e-prescribing market place," the EHR customer had "to enter into a contract that included those provisions if [the EHR] wanted to enter into e-prescribing."

161. Another Surescripts customer similarly feared that "Surescripts would have cut us off" if that customer did not sign an exclusive agreement with Surescripts.

162. Surescripts today thus no longer competes on the merits, but instead relies on its size, its ability to force customers into exclusivity, and the success of its loyalty program to maintain its monopolies.

**C. Surescripts's conduct has led to higher net prices for routing and eligibility.**

163. As Surescripts's then-Vice President of Corporate Strategy testified: "[P]ricing isn't dictated by competition at Surescripts."

164. But for Surescripts's anticompetitive course of conduct, the net price (taking into account both sides of the network) of the routing transaction would be lower. Similarly, without Surescripts's loyalty contracts, the net price (taking into account both sides of the network) of the eligibility transaction would be lower.

165. The handful of instances where a single customer uses both the Surescripts network and the Emdeon network shows that Emdeon is able to provide lower per-transaction prices or higher per-transaction incentives.

166. For example, Kroger is one of the last companies that uses both Emdeon and Surescripts via RelayHealth for routing. Emdeon charges Kroger pharmacies per-transaction prices that are lower than Surescripts's prices. Similarly, Emdeon has sold the routing transaction to one PTV customer, Rx30, at a per-transaction price that was lower than Surescripts's per-transaction price, and has offered to sell to another PTV customer, QS/1, at a per-transaction price that was lower than Surescripts's.

167. For eligibility, Emdeon offered prices that were lower than Surescripts's. A Surescripts PBM sales employee noted on May 20, 2015 that "competitors are under-pricing us such as Em[deon] with Eligibility. We are hearing that Emdeon is committing to promising half of our rate . . . . We are starting to hear a significant amount of concern that our price is too high . . . . Emdeon is making an aggressive [effort] now towards MedImpact. They are about [to] launch a pilot together [resulting] in a [lower] transaction rate." Yet there is no evidence that Surescripts attempted to match Emdeon's price for eligibility. Additionally, Allscripts charged at least one PBM (a PBM that had a direct connection with Allscripts) a price that was lower than what that same PBM was currently paying to Surescripts for the same eligibility transaction.

168. On the EHR side, Surescripts understood and acknowledged its ability to price above the competitive level. In an email exchange concerning EHR eClinicalWorks's attempts to negotiate for higher incentive payments, one Surescripts executive explained to another that "[ eClinicalWorks's] position in negotiating for more and more \$\$ only seems relevant when there are at least 5 more 'Surescripts' from which to choose. Today there is just one Surescripts."

169. Emdeon was willing to pay higher incentives to EHRs. For example, in 2010 Emdeon paid Allscripts incentives that were higher than what Surescripts and RelayHealth paid Allscripts. And Emdeon continued to pay Allscripts incentives that were higher than Surescripts's until Allscripts was forced to disconnect from Emdeon in June 2013. Emdeon has also offered to pay higher incentives to EHRs.

170. Because the loyalty contracts limited competitors' expansion, and thereby reduced pharmacies', PBMs', and EHRs' leverage with Surescripts, the contracts have enabled Surescripts, free from competitive discipline, to continue to demand higher prices from customers.

171. For example, in April 2012, Surescripts increased transaction prices (by decreasing incentive payments) on all EHRs for both routing and eligibility. In contemporaneous documents, Surescripts recognized that it was able to use its monopoly power to take money away from EHRs by decreasing these incentive payments. Indeed, no EHR was able to avoid these incentive payment reductions. No EHR moved its business to a Surescripts competitor or refused to do business with Surescripts as a result of this price increase.

172. As another example, in July 2013, Surescripts analyzed the impact of Allscripts's June 20, 2013 termination of its relationship with Emdeon, which Surescripts

required Allscripts to do in the 2010 Surescripts-Allscripts agreement. In a presentation that was circulated and commented on by senior Surescripts executives, Surescripts concluded that, because Allscripts had to stop using the cheaper Emdeon network and now had to route its volume through the more expensive Surescripts network, those few pharmacy customers that were not loyal to Surescripts were “feeling economic pain” and “paying ‘more at the pump.’” This same presentation calculated exactly how much “economic pain” its pharmacy customers such as Kroger were experiencing: Because Kroger no longer got its Allscripts prescriptions at Emdeon’s lower per-transaction rate, but now had to pay Surescripts’s higher per transaction rate. Kroger documented that the result of being forced to pay Surescripts’s higher prices meant that its routing costs “increased significantly,” by approximately 25%.

**D. Surescripts’s conduct has reduced innovation in routing and eligibility.**

173. Surescripts’s dominance over routing and eligibility has allowed it to control the rate of innovation, or lack thereof. A lack of competitive discipline and customers’ inability to change e-prescribing vendors has led to reduced innovation in e-prescribing. As one RelayHealth senior executive testified: “I can tell that in general that the industry wants e-prescribing to evolve, and it’s not.”

174. Surescripts agrees. As Surescripts’s former Chief Strategy Officer testified, from the time he joined Surescripts until when he left in 2012, that he “saw a bloated organization that wasn’t lowering cost, not delivering where people would feel like they were true customers.” A January 2013 Surescripts presentation forwarded to Surescripts’s Executive Vice President and Chief Customer Officer summarized the issue aptly: “There’s a ‘we’ve got such a dominant market position in e-prescriptions, who’s going to come in and threaten us?’ attitude.”

175. Surescripts's agreements with RelayHealth provide examples of how, in RelayHealth's words, "[t]he current [RelayHealth] relationship with [Surescripts] ... inhibits innovation."

176. Significantly, this innovation would have occurred in not just the routing market, but also in the eligibility market. Because of Surescripts' s conduct, however, consumers have had to wait many years to receive the benefits of such innovation, if consumers ever received those benefits at all.

177. For example, the 2010 Surescripts-RelayHealth contract called for the two companies to co-develop an initial list of 27 different value-added services, including Adherence Monitoring, Prescription History to Hospitals, Print @ Patient Cell Phone, Rx Claim Pre- Adjudication, Real-Time Benefit Check, electronic Prior Authentication, and REMS-related services such as prohibiting the prescribing/dispensing of medications with Risk Evaluation and Mitigation Strategies.

178. Not one joint Surescripts-RelayHealth value-added product or service resulted from the 2010 contract.

179. Similarly, not one joint Surescripts-RelayHealth product or service has resulted from the 2015 contract.

180. As alleged above, Surescripts repeatedly described the sole value of its agreements with RelayHealth as keeping RelayHealth's customers exclusive to Surescripts and preventing RelayHealth from competing against Surescripts in routing.

181. On numerous occasions, RelayHealth unsuccessfully attempted to collaborate with Surescripts to develop these value-added services. One RelayHealth executive testified that Surescripts proved to be "not very innovative or cooperative when it comes to value-

added services” and that Surescripts’s “words were much rosier than their actions, and [RelayHealth] presented many solutions from a value-add perspective, and they seemed to fall on deaf ears, and they were not pursued.” The failure of Surescripts and RelayHealth to collaborate “wasn’t for a lack of trying on [RelayHealth’s] part.” Surescripts never provided an explanation to RelayHealth as to why Surescripts chose not to collaborate with RelayHealth on any value-added services listed in the 2010 contract.

182. For example, the 2010 contract called for Surescripts and RelayHealth to co-develop a real-time benefit check service that would represent a significant improvement over Surescripts’s existing eligibility service. Unlike Surescripts’s eligibility offering, which relied on non-patient-specific, static formulary information, real-time benefit check allows a PBM to transmit patient-specific, real-time formulary information to physicians. Surescripts has known how to transmit such real-time formulary information since 2005, and RelayHealth expected to co-develop this service after the signing of the 2010 contract. Indeed, RelayHealth brought up this and other value-added services proposals at quarterly business meetings with Surescripts from 2012 to 2014. Surescripts never engaged with RelayHealth in developing real-time benefit check. Surescripts never shared any confidential or proprietary data, information, or technology with RelayHealth concerning real-time benefit check or other value-added services.

183. Only once RelayHealth understood that Surescripts had no intention to collaborate did RelayHealth develop value-added services such as real-time benefit check on its own. As early as 2013, RelayHealth began efforts to develop a real-time benefit check solution by itself, which RelayHealth brought to market in 2017. At that point, facing competition from RelayHealth, Surescripts finally brought its own real-time benefit check service to market.

184. The harms from Surescripts's conduct with respect to RelayHealth continue through today. The 2015 Surescripts-RelayHealth agreement, which is currently in effect, contains an implicit non-compete that prevents RelayHealth from competing against Surescripts in routing.

185. Had Surescripts not completely excluded all competition from the relevant markets-whether it was Emdeon, RelayHealth, Allscripts, or otherwise-competitive forces would have spurred Surescripts to innovate faster, bringing (or trying to bring) services such as real-time benefit check to the market earlier. Consumers were harmed as a result of these significant innovation delays.

**E. Surescripts's conduct has reduced quality in routing and eligibility.**

186. Similarly, because Surescripts faces no competition, it also has no incentive to improve its services, resulting in reduced quality to its customers. Again, Surescripts agrees: In 2015, Surescripts wrote, “[b]ecause we didn’t grow up in a competitive environment and we grew up as a monopoly, we don’t have the best way of dealing with customers.”

187. Customers agree. They have echoed these critiques, complaining that Surescripts has poor customer service, is slow to innovate, impedes EHRs’ ability to innovate due to stringent certification requirements, and uses opaque pricing strategies. Surescripts’s own executives report that customers use the following words to describe Surescripts: “monopoly,” “entrenched,” “slow,” “difficult,” “misleading,” “challenging,” “inconsistent,” and “dictates.”

188. To take one example, as early as January 2011 Surescripts knew that many of its pharmacy customers were dissatisfied with Surescripts’s service surrounding a specific type of routing transaction called “Denied, NewRx to Follow” or “DNTF,” which small, independent

pharmacies believed—correctly—caused Surescripts to double-bill the pharmacies for a single transaction. In October 2012, Surescripts calculated that it was taking in substantial amounts in DNTF transaction charges despite knowing that this was “a hot issue for independent pharmacies.” Surescripts, however, did not change its practices on DNTF until April 2013, 27 months after Surescripts’s senior executives knew that Surescripts was double-billing its routing customers.

189. Had Surescripts’s anticompetitive conduct not allowed it to maintain its monopoly status, consumers would have been able to choose other options that could have provided better customer service, or at least provided a competitive threat to spur Surescripts to improve the quality of its own services. But because Surescripts has unlawfully maintained its monopolies through its exclusive dealing and other anticompetitive arrangements with RelayHealth and Allscripts, consumers have been denied the quality improvements that competition brings.

**F. Surescripts’s conduct has reduced quality-adjusted output and overall transaction output.**

190. Surescripts’s conduct has reduced innovation and thus has also reduced quality-adjusted output. But for Surescripts’s conduct, there would be more and faster innovation in the routing and eligibility markets.

191. In addition to quality-adjusted output, Surescripts’s conduct has also reduced output as measured by transaction volume. As of 2017, 69% of doctors were utilizing e-prescribing. But for Surescripts’s conduct, competition for prescribers (via their EHRs) would likely result in higher incentive payments to EHRs, which would in turn provide incentives to EHRs to increase its doctors’ utilization of e-prescribing. At least one EHR welcomed the idea of higher incentives tied to growth: “[W]e would welcome an additional

‘target’ level whereby the incentive would increase ... as the volume grows.” And Allscripts told Surescripts that higher incentives tied to volume instead of loyalty would allow it to commit “to an increase in electronic prescription transactions from all our products through the Surescripts network.” Surescripts, however, rejected these options in favor of contractual language that implemented its loyalty scheme.

192. Additionally, Surescripts’s stringent certification requirements have delayed adoption and utilization of e-prescribing. Absent the restraints, increased price, innovation, and quality competition among networks for EHR volume would likely further incentivize or enable EHRs to increase the utilization of e-prescribing among doctors.

**G. There is no legitimate procompetitive business justification for Surescripts’s conduct.**

193. As the Senior Vice President of one of Surescripts’s large hospital system customers wrote in a March 2, 2011 letter to Surescripts’s CEO expressing his “deep concern” about Surescripts’s exclusivity requirements: “There is no conceivable justification for this policy other than Surescripts’ desire to maintain an e-prescribing monopoly.”

194. Surescripts’s exclusivity requirements do not serve any legitimate procompetitive business purpose. Increases in adoption and utilization were largely driven by incentives under MIPPA, the HITECH Act, and a broader movement towards computerized health records generally. While incentive payments to EHRs may increase output, the exclusivity provisions to which those incentives are tied do not enhance or otherwise further the adoption or utilization of e-prescribing.

195. Surescripts’s exclusivity requirements were not reasonably necessary to reduce prices. Moreover, Surescripts could have accomplished this objective through less restrictive alternatives, primarily through discounts based on volume, not loyalty.

196. Surescripts is not a natural monopoly. E-prescribing customers treat Surescripts like any other vendor, seeking out alternatives to Surescripts for routing and eligibility. A small number of customers use multiple networks. At least one smaller-scale competitor, Emdeon, has offered lower pricing and higher incentive payments.

197. There is no legitimate procompetitive justification for the features in Surescripts's contracts with Allscripts. Indeed, though it was only after Surescripts became aware of the FTC's investigation, Surescripts and Allscripts dropped many of these provisions, yet Surescripts is still able to provide routing and eligibility services to Allscripts today.

198. There is no legitimate procompetitive justification for Surescripts's routing non- compete with RelayHealth. Other provisions in the 2010 contract provided strong protections for any of Surescripts' s proprietary information. Any proprietary information disclosed by either party to the other in connection with the agreement was protected by the recipient party from disclosure to others. Any documentation provided by Surescripts under the 2010 contract was designated proprietary to Surescripts, and RelayHealth could not copy or use that documentation in any way other than as specifically authorized by the agreement.

199. Plaintiffs and members of the Class had no knowledge of Defendants' unlawful self-concealing scheme and could not have discovered the scheme and conspiracy through the exercise of reasonable diligence more than four years prior to the filing of this Complaint.

200. This is the case because the nature of Defendants' conspiracy was self-concealing and because Defendants employed deceptive practices and techniques of secrecy to avoid detection of, and to fraudulently conceal, their contract, combination, conspiracy and scheme. Notwithstanding the self-concealing nature of their conspiracy, Defendants and their

co-conspirators wrongfully and affirmatively concealed the existence of their continuing combination and conspiracy from Plaintiffs by, among other things, concealing from Plaintiffs and the public the exclusive nature of the loyalty contracts between Surescripts and RelayHealth, Surescripts and Allscripts, and between Surescripts, RelayHealth, and PTV Co-Conspirators.

201. Because the alleged conspiracy was both self-concealing and affirmatively concealed by Defendants and their co-conspirators, Plaintiffs and members of the Class had no knowledge of the alleged conspiracy, or of any facts or information that would have caused a reasonably diligent person to investigate whether a conspiracy existed, until May 3, 2019 at the earliest, when the Federal Trade Commission filed a complaint in the United States District Court for the District of Columbia alleging a Surescripts scheme to monopolize routing and eligibility markets.

202. As a result of Defendants' fraudulent concealment, all applicable statutes of limitations affecting the Plaintiffs and the Class's claims have been tolled.

### **VIII. ANTITRUST IMPACT AND IMPACT ON INTERSTATE CONDUCT**

203. During the relevant period, Plaintiffs and members of the Class paid substantial overcharges on routing transactions directly from Surescripts, RelayHealth, and PTV Co-Conspirators. As a result of the illegal conduct alleged in this complaint, members of the Class were compelled to pay, and did pay, artificially inflated prices for their routing transactions.

204. Consequently, Plaintiffs and members of the Class have sustained substantial losses and damage to their business and property in the form of overcharges. The full amount,

form, and components of such damages will be calculated after discovery and upon proof at trial.

205. Defendants' efforts to monopolize and restrain competition in the market for routing and eligibility have substantially affected interstate commerce.

206. At all material times, Defendants sold e-prescription routing and eligibility in a continuous and uninterrupted flow of commerce across state and national lines and throughout the United States.

207. At all material times, Defendants transmitted funds as well as contracts, invoices and other forms of business communications and transactions in a continuous and uninterrupted flow of commerce across state and national lines in connection with the sale of e-prescription routing and eligibility.

#### **VIV. CLASS ACTION ALLEGATIONS**

208. Plaintiffs, on behalf of themselves and all Class members, seek damages, measured as overcharges, trebled, against Defendants based on allegations of anticompetitive conduct in the markets for routing and eligibility.

209. Plaintiffs bring this action on behalf of themselves and, under Federal Rule of Civil Procedure 23(a), (b)(2), and (b)(3), as representatives of a Class defined as follows:

All pharmacies in the United States and its territories who paid for e-prescription routing transactions from Surescripts, RelayHealth, or any pharmacy technology vendor with an exclusive Surescripts or RelayHealth routing contract during the period September 21, 2010, through and until the date of trial.

Excluded from the Class are Defendants and their officers, directors, management, employees, subsidiaries, or affiliates, and all governmental entities.

210. Members of the Class are so numerous that joinder is impracticable. Plaintiffs believe that the Class numbers in the tens of thousands. Further, the Class is readily identifiable from information and records in Defendants' possession.

211. Plaintiffs' claims are typical of the claims of the members of the Class. Plaintiffs and all members of the Class were damaged by the same wrongful conduct of the Defendants, i.e., they paid artificially inflated prices for e-prescription routing and were deprived of earlier and more robust competition from cheaper competitors as a result of Defendants' wrongful conduct.

212. Plaintiffs will fairly and adequately protect and represent the interests of the Class. The interests of the Plaintiffs are coincident with, and not antagonistic to, those of the Class.

213. Plaintiffs are represented by counsel with experience in the prosecution of class action antitrust litigation, and with particular experience with class action antitrust litigation involving the healthcare industry.

214. Questions of law and fact common to the members of the Class predominate over questions that may affect only individual class members because Defendants have acted on grounds generally applicable to the entire Class thereby making overcharge damages with respect to the Class as a whole appropriate. Such generally applicable conduct is inherent in Defendants' wrongful conduct.

215. Questions of law and fact common to the Class include:

- A. Whether Surescripts willfully obtained and maintained market power over e-prescription routing;
- B. Whether Surescripts unlawfully excluded competitors and potential competitors from the markets for routing and eligibility;

- C. Whether Surescripts has any legally cognizable procompetitive benefit that could not have been achieved using a means with less restrictions on competition, and if so, whether the anticompetitive effect of Surescripts' misconduct nonetheless outweighs the procompetitive benefit;
- D. Whether Surescripts entered into an illegal agreement with RelayHealth not to compete and to allocate the routing market to Surescripts;
- E. Whether the unlawful scheme alleged herein has substantially affected interstate commerce;
- F. Whether Defendants' anticompetitive conduct caused antitrust impact to Plaintiffs and members of the class; and
- G. The quantum of aggregate overcharge damages to the class.

216. Class action treatment is a superior method for the fair and efficient adjudication of the controversy. Such treatment will permit a large number of similarly-situated persons to prosecute their common claims in a single forum simultaneously, efficiently, and without the unnecessary duplication of evidence, effort, or expense that numerous individual actions would engender. The benefits of proceeding through the class mechanism, including providing injured persons or entities a method for obtaining redress on claims that could not practicably be pursued individually, substantially outweighs potential difficulties in management of this class action.

217. Plaintiffs know of no special difficulty to be encountered in the maintenance of this action that would preclude its maintenance as a class action.

### **CLAIMS FOR RELIEF**

#### **CLAIM I – MONOPOLIZATION VIOLATION OF SECTION 2 OF THE SHERMAN ACT (15 U.S.C. § 2) (ASSERTED AGAINST SURESCRIPTS)**

218. Plaintiffs repeat and incorporate by reference all preceding paragraphs and allegations.

219. As described above, from approximately September 2010 to the present, Surescripts possessed monopoly power in the markets for e-prescription routing and eligibility. No other competitor has been able to restrain Surescripts' ability to charge supracompetitive monopoly prices for routing transactions during the relevant time period. Surescripts had and has the ability to control prices and exclude competitors.

220. Surescripts willfully and unlawfully maintained its market power in the routing market by engaging in an anticompetitive scheme to prevent legitimate competition on the merits. Surescripts' monopolies have been maintained by its anticompetitive conduct and not as a result of providing a superior product, business acumen, or historical accident.

221. Surescripts' course of anticompetitive conduct includes its exclusive or de facto exclusive agreements with pharmacies, PTV Co-Conspirators, and EHRs, requiring those entities to use the Surescripts network exclusively or nearly exclusively for routing, as well as the non-compete provisions in its contracts with RelayHealth. Collectively, Surescripts' contracts substantially foreclose the routing market from actual and potential competition.

222. There are no valid procompetitive justifications for Surescripts' exclusionary conduct in the routing market and even if there were (and there are not), any such ostensible procompetitive benefit could have been obtained through a less restrictive means.

223. By means of this scheme, Plaintiffs and members of the Class paid artificially inflated prices for routing transactions, for nearly a decade. Plaintiffs and members of the Class have been injured in their property by Surescripts' antitrust violations. Their injury consists of having paid, and continuing to pay, higher prices for routing transactions than they would have paid absent Surescripts' scheme. Such injury is of the type antitrust laws were designed to

prevent and flows from that which makes Surescripts' conduct unlawful. Plaintiffs are the proper entities to bring a private case concerning this conduct.

224. Surescripts' anticompetitive acts violate Section 2 of the Sherman Act.

**CLAIM II – CONSPIRACY TO MONOPOLIZE  
VIOLATION OF SECTION 2 OF THE SHERMAN ACT (15 U.S.C. § 2)  
(ASSERTED AGAINST SURESCRIPTS AND RELAYHEALTH)**

225. Plaintiffs repeat and incorporate by reference all preceding paragraphs and allegations.

226. As described above, from approximately September 2010 to the present, Surescripts possessed monopoly power in the markets for e-prescription routing and eligibility. No other competitor has been able to restrain Surescripts' ability to charge supracompetitive monopoly prices for routing transactions during the relevant time period. Surescripts had and has the ability to control prices and exclude competitors.

227. In addition to agreeing to express and per se unlawful contracts in restraint of trade with Surescripts, RelayHealth conspired with Surescripts to unlawfully maintain Surescripts' monopoly over the routing market. In coordination with Surescripts, RelayHealth and PTV Co-Conspirators effectively required pharmacy customers to use only the Surescripts routing network, furthering Surescripts' goal of maintaining its monopolies with a market-wide web of anticompetitive loyalty contracts.

228. In return for requiring their own customers to remain loyal to Surescripts and eschew competitors' offers, RelayHealth and PTV Co-Conspirators received a share of the supracompetitive profits that Surescripts secured through its monopolies. This payment took the form of increased margin, or "spread," between the price Surescripts charged RelayHealth and PTV Co-Conspirators for routing transactions and the price RelayHealth and PTV Co-Conspirators could charge pharmacies.

229. The goal, purpose, and effect of the Surescripts-directed conspiracy was to maintain and extend Surescripts' monopoly over the routing market so as to ensure continued monopoly profits for Defendants and to effectively fix e-prescription routing prices.

230. As a direct and proximate result of the conspiracy to monopolize, Plaintiffs and the members of the Class paid artificially inflated prices for routing transactions and were harmed as a result. These injuries are of the type the Sherman Act was designed to prevent, and flow from that which makes Surescripts' and RelayHealth's conduct unlawful.

231. By engaging in the foregoing conduct, Surescripts and RelayHealth have intentionally and wrongfully conspired to monopolize in violation of the Sherman Act.

232. But for the unlawful conspiracy to monopolize between Surescripts, RelayHealth, and PTV Co-Conspirators, RelayHealth and other potential routing competitors would have competed in the routing market, leading to lower routing prices for Plaintiffs and members of the Class.

**CLAIM III – CONSPIRACY/COMBINATION IN RESTRAINT OF TRADE  
VIOLATION OF SECTION 1 OF THE SHERMAN ACT (15 U.S.C. § 1)  
(ASSERTED AGAINST SURESCRIPTS AND RELAYHEALTH)**

233. Plaintiffs repeat and incorporate by reference all preceding paragraphs and allegations.

234. As described above, from approximately September 2010 to the present, Surescripts possessed market power in the markets for e-prescription routing and eligibility; Surescripts had and has the ability to control prices and exclude competitors.

235. In and around February 2010, in response to potential competition, Surescripts entered into an unlawful agreement with RelayHealth that prohibited RelayHealth from competing against Surescripts in the routing market. Although couched as a continuation of the existing “value-added reseller” relationship between Surescripts and RelayHealth, this agreement was in fact a naked agreement not to compete and to allocate markets among actual and potential horizontal competitors and is a per se violation of the antitrust laws.

236. Alternatively, even if found not to be a per se violation of the antitrust laws, the February 2010 Surescripts/RelayHealth agreement is a violation under the rule of reason framework; there is no valid procompetitive justification for the agreement to restraint trade and even if there was (and there is not), any ostensible procompetitive benefit could have been achieved through lesser restrictive means.

237. In or around January 2015, Surescripts and RelayHealth renewed the agreement not to compete, and for Surescripts to remain the sole provider of routing services to RelayHealth’s routing resale operations. RelayHealth also agreed to abandon its position in the EHR market and surrendered its EHRs to Surescripts. This agreement expanded upon and continued the per se unlawful market allocation/agreement not to compete from 2010. An internal competition analysis from Surescripts at the time characterized RelayHealth as a “Core Systemic [Competitor].” Celebrating the agreement that neutralized the competitive threat, Surescripts’ Chief Quality Officer emailed Surescripts’ Vice President of Customer Accounts and congratulated him by noting that “I would not want to have Relay out there competing directly against us.” For its part in the scheme, RelayHealth was allowed a portion of the supracompetitive routing profits.

238. As of today, RelayHealth has not entered the routing market.

239. The purpose and effect of the agreements between Surescripts and RelayHealth and PTV Co-Conspirators was to eliminate competition in the routing market, allocate supracompetitive profits among competitors, and effectively fix e-prescription routing prices, all at the expense of Plaintiffs and the Class.

240. As a direct and proximate result of the unlawful restraint of trade between Surescripts, RelayHealth, and PTV Co-Conspirators, Plaintiffs and the members of the Class paid artificially inflated prices for routing transactions and were harmed as a result. These injuries are of the type the Sherman Act was designed to prevent, and flow from that which makes Surescripts' and RelayHealth's conduct unlawful.

241. By engaging in the foregoing conduct, Surescripts and RelayHealth have intentionally and wrongfully engaged in one or more combinations and conspiracies in restraint of trade in violation of the Sherman Act.

242. But for the unlawful agreements between Surescripts and RelayHealth, RelayHealth and other potential routing competitors would have competed in the routing market, leading to lower routing prices for Plaintiffs and members of the Class.

**CLAIM IV – CONSPIRACY/COMBINATION IN RESTRAINT OF TRADE  
VIOLATION OF SECTION 1 OF THE SHERMAN ACT (15 U.S.C. § 1)  
(ASSERTED AGAINST SURESCRIPTS AND ALLSCRIPTS)**

243. Plaintiffs repeat and incorporate by reference all preceding paragraphs and allegations.

244. As described above, from approximately September 2010 to the present, Surescripts possessed market power in the markets for e-prescription routing and eligibility; Surescripts had and has the ability to control prices and exclude competitors.

245. On or about May 31, 2010, Surescripts and Allscripts entered into an unlawful contract in restraint of trade that effectively eliminated Emdeon as a potential competitor in the routing market and ensured that nascent competitors in the routing market would not be able to access Allscripts' sizeable EHR marketshare. The purpose and effect of the 2010 Surescripts- Allscripts agreement was to maintain Surescripts' monopolies; in return for joining the conspiracy, Allscripts received payments from Surescripts— out of its supracompetitive monopoly profits— in the form of higher-than-market incentive payments.

246. Surescripts described an early version of this Allscripts agreement with a picture of a movie containing the slogan "HERE COMES THE BRIBE."

247. Surescripts and Allscripts continued their agreement in restraint of trade through a 2015 contract that extended the exclusivity and revenue sharing provisions for another five years.

248. The purpose and effect of the agreements between Surescripts and Allscripts was to eliminate competition in the routing market, share supracompetitive profits, and effectively fix e-prescription routing prices, at the expense of Plaintiffs and the Class.

249. As a direct and proximate result of Surescripts' and Allscripts' unlawful restraint of trade, Plaintiffs and the members of the Class paid artificially inflated prices for routing transactions and were harmed as a result. These injuries are of the type the Sherman Act was designed to prevent, and flow from that which makes Surescripts' and Allscripts' conduct unlawful.

250. By engaging in the foregoing conduct, Surescripts and Allscripts have intentionally and wrongfully engaged in one or more combinations and conspiracies in restraint of trade in violation of the Sherman Act.

251. But for the unlawful agreements between Surescripts and Allscripts, other potential routing competitors would have competed in the routing market, leading to lower routing prices for Plaintiffs and members of the Class.

### **DEMAND FOR JUDGMENT**

252. WHEREFORE, Plaintiffs, on behalf of themselves and the proposed Class, respectfully pray that the Court:

- A.** Determine that this action may be maintained as a class action pursuant to Fed. R. Civ. P. 23(a), (b)(2) and (b)(3); direct that reasonable notice of this action, as provided by Fed. R. Civ. P. 23(c)(2) be given to the Class; and declare that Plaintiffs are the representatives of the Class;
- B.** Enter joint and several judgments against Defendants and in favor of Plaintiffs and the Class;
- C.** Declare the acts alleged herein to be unlawful under the state statutes set forth above;
- D.** Award Plaintiffs damages as provided by law in the amount to be determined at trial;
- E.** Award the Class damages and, if applicable, treble, multiple, punitive and/or other damages, in the amount to be determined at trial, including interest; Award Plaintiffs and the Class the costs of this suit, including reasonable attorneys' fees as provided by law; and
- F.** Grant such other further relief as is necessary to correct for the anticompetitive market effects caused by Defendants' unlawful conduct as the Court deems appropriate.

**JURY DEMAND**

253. Plaintiffs demand a trial by jury on all issues so triable.

Dated: October 25, 2019

WEXLER WALLACE LLP  
By: /s/Kenneth A. Wexler  
Kenneth A. Wexler  
Justin N. Boley  
Tyler J. Story  
55 West Monroe St., Ste. 3300  
Chicago, IL 60603  
T: (312) 346-2222  
F: (312) 346-0022  
kaw@wexlerwallace.com  
jnb@wexlerwallace.com  
tjs@wexlerwallace.com

KAPLAN FOX & KILSHEIMER LLP  
Robert N. Kaplan, Esq.  
Jeffrey P. Campisi, Esq.  
Elana Katcher, Esq.  
Matthew P. McCahill, Esq.  
850 Third Ave., 14th Floor  
New York, NY 10022  
Telephone: (212) 687-1980  
Email: rkaplan@kaplanfox.com  
Email: jcampisi@kaplanfox.com  
Email: ekatcher@kaplanfox.com  
Email: mmccahill@kaplanfox.com

Kaplan Fox & Kilsheimer LLP  
Gary Specks  
681 Prestwick Lane  
Wheeling, Illinois 60090  
Tele.: 847.831.1585  
Fax.: 847.831.1580  
Email: gspecks@kaplanfox.com

*Counsel for Plaintiff and the Proposed Class*